Janus was founded in 2004 by “,
a clinical development services company in the United States and aRigen,
Inc., a private equity backed bio-medical venture
company in Japan. aRigen and CPG identified the value in creating topical
formulations of novel anti-infective products discovered in Japan and
developing and commercializing these products in the United States.
Janus has assembled an experienced management team and board of directors
in the US and Japan with an impressive track-record and network of
contacts on both sides of the Pacific. Janus is actively seeking to acquire
promising products and compounds that will complement our business strategy
and to which we can add value to via our clinical development and commercialization
Janus has a license agreement with aRigen for ” (WAP-8294A2)
and a joint development agreement for ” (ARYS-01)
with aRigen. Furthermore, the companies plan to continue to work
together to leverage their respective capabilites and expand their
mutual product portfolio. In addition, Janus intends to build on each strategic
alliance by identifying additional markets and indications for each
of the products
CPG provides contiguous and integrated clinical
development programs from IND to NDA for Japanese pharmaceutical
and biotech companies interested in entering the US market. CPG has
two subsidiaries, Catalyst Pharmaceutical Research LLC, a premier
clinical research organization (CRO) and Healthcare Discoveries Inc.,
a Phase 1 services organization.
About aRigen Inc.
and develops under valued assets from Japanese pharmaceutical firms,
public research institutes and universities. In a few short years,
aRigen has acquired a large product portfolio, with several products rapidly
advancing into clinical development. In part, because
of the success of aRigen in Japan, this business strategy is now
being extended to capture the United States market opportunity.